My research agenda is built on empirically understanding how firms manage innovation and make better decisions in the face of risk: from the loss of value due to the information asymmetries and uncertainties between supply chain partners, to the wrong investments in a pharmaceutical firm’s portfolio of drug development projects.  

Peer-Reviewed Publications

[4] Turcic, D., P. Markou, P. Kouvelis, and D. Corsten. (2023). “Automotive Procurement Under Opaque Prices: Theory with Evidence from the BMW Supply Chain." Management Science, Accepted.

[3] Markou, P., S. Kavadias, and N. Oraiopoulos. (2022). “Project Selection and Success: Insights from the Drug Development Process." Management Science, Accepted.

[2] Markou, P. and D. Corsten. (2021). “Financial and Operational Risk Management: Inventory Effects in the Gold Mining Industry." Production & Operations Management, 30(12), pp. 4635-4655.

[1] Luffarelli, J., P. Markou, A. Stamatogiannakis, D. Goncalves. (2019). “The effect of corporate social performance on the financial performance of business‐to‐business and business‐to‐consumer firms." Corporate Social Responsibility and Environmental Management, 26(6), pp.1333-1350.

Book Chapters and Practitioner Articles

[3] Markou, P., D. Corsten, C. Carduck, and M. Koblbauer. (2019). “Commodity Risk Management at BMW: Price Indices and Contracts”. In Tate, W., Bals, L., and Ellram, L., eds. Supply Chain Finance: Risk Management, Resilience and Supplier Management, Kogan Page, Ch. 9, pp.177-194.

[2] Markou, P. and D. Corsten. (2017). “Linking Commodity Price Risk and Operations: Evidence from the Gold Mining Industry”. In Kouvelis, P., Dong, L., and Turcic, D., eds. Foundations and Trends in Technology, Information and Operations Management. 11(1-2), pp.165-185.

[1] Markou, P. and D. Corsten. (2017). “Trade Credit: A Fresh Look.” World Supply Chain Finance Report 2017. BCR Publishing, pp.14-16. 

Working Papers